Cellectar Biosciences Inc (CLRB) FinancialsCLRBFinancialCellectar Biosciences Inc

Evaluating the bottom line, Cellectar Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -125.99%, provide a clear picture of how effectively CLRB converts its operational activities into shareholder value.

In the context of the broader market, CLRB competes directly with industry leaders such as AYTU and BFRI. With a market capitalization of $24.58M, it holds a significant position in the sector. When comparing efficiency, CLRB's gross margin of N/A stands against AYTU's 55.10% and BFRI's 79.92%. Such benchmarking helps identify whether Cellectar Biosciences Inc is trading at a premium or discount relative to its financial performance.

Cellectar's financial performance shows significant net losses, with a Q2 2026 net income loss of $6.9 million and a forward P/E ratio of 0, indicating no earnings expected in the near term.